Taking advantage of a broken patent system, Big Pharma is making minor tweaks to medications just to keep affordable generics ...

Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Eli Lilly's Zepbound is the first and only approved dual GLP-1/GIP agonist, and Lilly is also working on its own triple ...

Novo Nordisk is looking to partner with digital companies at every stage of the weight loss journey to help patients lose ...

When it comes to healthcare stocks, many investors pay attention to the usual suspects: Eli Lilly, Novo Nordisk, CVS Health, or Johnson & Johnson. These companies have built up enormous brand equity ...

Indian drug companies are preparing to launch low-cost versions of Novo Nordisk’s Wegovy and Ozempic as patents expire in 2026, making weight-loss and diabetes treatment more affordable worldwide.

Landmark investments, portfolio progress, and expanded presence positionNovo Holdings for long-term growth and impact in Asia SINGAPORE, June 18, 2025 ...

As one of the important sub-sequences of "CIIE Stories", the "CIIE Babies" series will invite exhibitors from the global ...

In the aftermath of several deals with smaller biotechs made in the 13 months in the cardiometabolic space, Novo Nordisk has ...

A trial pitting weight loss jab Mounjaro against competitor Wegovy ended with one clear winner, and Mounjaro is getting ...

Novo Nordisk A/S (NYSE:NVO) is among the best bear market stocks to buy according to analysts. Novo Nordisk A/S (NYSE:NVO) ...

Bezons (France), June 17, 2025 - 6:00pm (CET) - RIBER, the global leader in Molecular Beam Epitaxy (MBE) equipment for the semiconductor industry, announces the signing of a three-year collaborative ...